BAJAJ BROKING
Apollo Hospitals Enterprise Ltd plans to invest ₹250 crore in India’s first Proteus One proton therapy system in Hyderabad. The facility, set to be operational by FY2028, will increase annual cancer treatment capacity by 350 patients. The investment is funded through internal accruals.
Apollo Hospitals Enterprise Ltd has announced a significant investment of ₹250 crore to establish India’s first Proteus One proton therapy system in Hyderabad. The advanced oncology centre will expand the hospital chain’s existing proton therapy capabilities and is expected to become operational by FY2028. The investment, fully funded through internal accruals, aims to enhance cancer treatment accessibility in India.
Also read: Dr Reddy’s Sells 14-Drug Portfolio to Senores Pharma for US Market Growth
Investment Amount: ₹250 crore
Facility Location: Hyderabad
Expected Operational Year: FY2028
Annual Treatment Capacity: 350 additional patients
Existing Chennai Proton Centre Capacity: 850 patients per year
Technology Partner: Ion Beam Applications (IBA)
Also read: Welspun Specialty Wins ₹231.77 Crore BHEL Contract for Boiler Tubes
Apollo Hospitals currently operates a proton therapy centre in Chennai, which treats over 500 cancer patients annually. The Chennai facility, designed for a capacity of 850 patients, was South Asia’s first proton therapy centre when launched in 2019. The new Hyderabad centre will add to this capacity, allowing an additional 350 patients to receive cutting-edge cancer treatment each year.
The Proteus One system, developed by Ion Beam Applications (IBA), is a state-of-the-art single-room proton therapy solution known for its precision and efficiency in targeting tumours. Proton therapy is widely recognised for its benefits in treating complex cancers, including central nervous system tumours, paediatric cancers, and head and neck malignancies.
Project Details | Information |
Investment Amount | ₹250 crore |
Location | Hyderabad |
Expected Completion | FY2028 |
Technology Provider | Ion Beam Applications (IBA) |
New Treatment Capacity | 350 additional patients/year |
Current Chennai Centre Capacity | 850 patients/year |
Following the announcement, Apollo Hospitals Enterprise Ltd share price closed at ₹6,183.45, reflecting a marginal gain of ₹6.30 or 0.10% on the BSE. Investors are closely monitoring the impact of this expansion on the company’s long-term growth in the healthcare sector.
Apollo Hospitals Enterprise Ltd continues to strengthen its position as a leader in cancer care by introducing advanced treatment solutions in India. The ₹250 crore investment in Hyderabad’s Proteus One system highlights its commitment to expanding proton therapy, improving patient outcomes, and enhancing its oncology infrastructure. With the project set to be completed by FY2028, Apollo Hospitals is poised to redefine cancer treatment accessibility in the country.
Also read: Power Grid Wins Bids for 3 Interstate Transmission Projects Under BOOT Model
Do you have a trading account app or demat account app?
You can open an account with Bajaj Broking in minutes.
Download the Bajaj Broking app now from Play Store or App Store.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://www.bajajbroking.in/disclaimer
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading